Vinblastine

Vinca Alkaloid — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Vinblastine is an ofp drug in the Vinca Alkaloid class catalogued in DrugCentral. It was first approved by the FDA in 1965. DrugCentral lists 11 molecular targets, including TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8, ABCB1 and TBXAS1. Recorded indications include Carcinoma of female breast, Gestational trophoblastic neoplasia, Hodgkin's disease and Kaposi's sarcoma.

• Approval status: ofp (first approved 1965 by the FDA).
• Drug class: Vinca Alkaloid.
• Molecular targets: TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8, ABCB1, TBXAS1 and PSMB1 (11 listed in DrugCentral).
• Indications: Carcinoma of female breast, Gestational trophoblastic neoplasia, Hodgkin's disease, Kaposi's sarcoma and Langerhans cell histiocytosis, disseminated and others.
• ATC code: L01CA01 (Vinca alkaloids and analogues).
• Molecular formula: C46H58N4O9; molecular weight 810.99 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (9)

• Carcinoma of female breast
• Gestational trophoblastic neoplasia
• Hodgkin's disease
• Kaposi's sarcoma
• Langerhans cell histiocytosis, disseminated
• Malignant tumor of testis
• Metastatic Breast Carcinoma
• Mycosis fungoides
• Non-Hodgkin's lymphoma

Off-label uses (5)

• Malignant tumor of head and/or neck
• Malignant tumor of urinary bladder
• Neuroblastoma
• Non-small cell lung cancer
• Ovarian Germ Cell Tumor Carcinoma

Contraindications (18)

• Bacterial infectious disease
• Bone marrow depression
• Breastfeeding (mother)
• Depressive disorder
• Disorder of lung
• Hepatic failure
• Hyperbilirubinemia
• Hyperuricemia
• Impaired wound healing
• Mycosis
• Myocardial ischemia
• Neutropenic disorder
• Peripheral nerve disease
• Pregnancy, function
• Protozoal Infection
• Severe Leukopenia
• Thrombocytopenic disorder
• Viral disease

Mechanism & targets

• Established pharmacologic class: Vinca Alkaloid

Molecular targets (11)

Target	Gene	Action	Activity
Tubulin beta	TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	inhibitor	IC50 9.00
Multidrug resistance protein 1	ABCB1	unknown	Ki 7.00
Thromboxane-A synthase	TBXAS1	unknown	IC50 5.73
Proteasome subunit beta type-1	PSMB1	unknown	IC50 5.37
Proteasome subunit beta type-5	PSMB5	unknown	IC50 5.34
Proteasome subunit beta type-2	PSMB2	unknown	IC50 5.31
Arachidonate 15-lipoxygenase	ALOX15	unknown	IC50 5.30
Amine oxidase [flavin-containing] B	MAOB	unknown	Ki 4.11
Multidrug resistance-associated protein 7	ABCC10	unknown	—
Canalicular multispecific organic anion transporter 1	ABCC2	unknown	—
Multidrug resistance-associated protein 1	ABCC1	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1965-11-05	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
L01CA01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS › Vinca alkaloids and analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Febrile neutropenia	912.1
Neutropenia	558.6
Second primary malignancy	521.5
Pulmonary toxicity	456.7
Acute myeloid leukaemia	344.1
Neuropathy peripheral	319.6
Disease progression	307.0
Off label use	208.3
Malignant neoplasm progression	181.6
Product use in unapproved indication	172.1
Cardiotoxicity	163.7
Pancytopenia	163.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Vinblastine is on its molecule page.

• Molecular formula: C₄₆H₅₈N₄O₉
• Molecular weight: 810.99 g/mol
• CAS number: 865-21-4
• InChIKey: JXLYSJRDGCGARV-CFWMRBGOSA-N
• PubChem CID: 13342

CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vinblastine used for?

DrugCentral lists the following indications for Vinblastine: Carcinoma of female breast, Gestational trophoblastic neoplasia, Hodgkin's disease, Kaposi's sarcoma, Langerhans cell histiocytosis, disseminated, Malignant tumor of testis, Metastatic Breast Carcinoma and Mycosis fungoides and others.

How does Vinblastine work?

Its molecular targets in DrugCentral include TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8 (inhibitor), ABCB1, TBXAS1 and PSMB1.

When was Vinblastine first approved?

Vinblastine was first approved by the FDA in 1965.

What drug class does Vinblastine belong to?

Vinblastine is in the Vinca Alkaloid class.

What is the chemical formula of Vinblastine?

Vinblastine has the molecular formula C46H58N4O9 and a molecular weight of 810.99 g/mol.

Sources

• DrugCentral drug card 2823 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL159 — compound record and bioactivity
• PubChem CID 13342 — chemical identifiers
• DrugBank DB00570 — drug record
• FDA UNII 5V9KLZ54CY — substance identity
• DailyMed: FDA labels for Vinblastine — current prescribing information (label search)
• UniProt P08183 (ABCB1) — target protein
• UniProt P24557 (TBXAS1) — target protein
• UniProt P20618 (PSMB1) — target protein
• UniProt P28074 (PSMB5) — target protein
• UniProt P49721 (PSMB2) — target protein
• UniProt Q5T3U5 (ABCC10) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.